Skip to content


Critical Care

Open Access

Immunomodulatory effects of esmolol in a septic animal model due to multidrug-resistant Pseudomonas aeruginosapyelonephritis

  • G Dimopoulos1,
  • T Tsaganos1,
  • M Theodorakopoulou1,
  • H Tzepi1,
  • M Lignos1,
  • A Armaganidis1 and
  • E Giamarellos-Bourboulis1
Critical Care200812(Suppl 2):P379

Published: 13 March 2008


Organ CulturePseudomonas AeruginosaMalondialdehydeThiobarbiturateAmikacin


The infusion of esmolol (a hypelective β1-blocker) is associated with immunomodulatory effects [1].


Eighty white rabbits underwent pyelonephritis (multidrug-resistant Pseudomonas aeruginosa) induction and classification in pretreatment (PT) (n = 40) (infusion of esmolol immediately after pyelonephritis induction) and treatment (T) (n = 40) (initial infusion of esmolol 2 hours after pyelonephritis induction) group. PT = group A (n = 10, control, N/S 0.9% infusion), group B (n = 10, esmolol infusion), group C (n = 10, amikacin infusion) and group D (n = 10, esmolol and amikacin infusion) and T = groups E, F, G and H having similar treatment. Serum malondialdehyde (MDA) was estimated at serial time intervals by the thiobarbiturate assay followed by HPLC analysis. The animals were under survival follow-up every 12 hours for the next 21 days. After death, quantitative organ cultures were performed.


Median (IQR) MDA at 24 hours was 1.95 (0.75), 0.78 (1.79), 1.55 (1.60) and 0.12 (0.24) μmol/ml in groups A, B, C and D, respectively. Respective values at 48 hours were 2.60 (2.00), 1.40 (2.36), 3.15 (3.00) and 0.25 (0.20) μmol/ml. At 24 hours, the median (IQR) MDA of groups E, F, G and H were 2.80 (5.74), 0.32 (0.87), 0.61 (5.83) and 0.19 (2.75) μmol/ml, respectively. Tissue bacterial load was similar within groups. See Figures 1 and 2.
Figure 1

Pretreatment group.

Figure 2

Treatment group.


In the present septic model, esmolol prolonged survival probably by exerting an immunomodulatory effect as assessed by reduced oxidative stress without any effect on tissue bacterial load.

Authors’ Affiliations

Medical School, University of Athens, Greece


  1. Suzuki T, et al: Crit Care Med. 2005, 33: 2294-2300. 10.1097/01.CCM.0000182796.11329.3B.PubMedView ArticleGoogle Scholar


© BioMed Central Ltd 2008

This article is published under license to BioMed Central Ltd.